Back to discover

Protein / target

Immunoglobulin heavy constant epsilon

IGHEP01854Homo sapiensSwiss-Prot
30
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Immunoglobulin receptor binding

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Constant region of immunoglobulin heavy chains.

View complete UniProt function annotation

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

Subcellular location

SecretedCell membrane
Domains and Gene Ontology detail (31)

Domains & features

Ig-like 1Ig-like 2Ig-like 3Ig-like 4

Gene Ontology

  • Cextracellular region
  • Cextracellular space
  • CIgE B cell receptor complex
  • Cimmunoglobulin complex, circulating
  • Cplasma membrane
  • Fantigen binding
  • Fimmunoglobulin receptor binding
  • Padaptive immune memory response
  • Padaptive immune response
  • Pantibacterial humoral response
  • Pantibody-dependent cellular cytotoxicity
  • PB cell activation

546 aa · 60 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GO
View supporting evidence

Immune signalling

  • ·Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodie…
  • ·IgE B cell receptor complex
  • ·antigen binding
  • ·adaptive immune response

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Asthma1 medicine
Lung Diseases, Obstructive1 medicine
Rhinitis1 medicine
Urticaria1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

omalizumab
Narrow target profileInhibitor

Ig epsilon chain C region inhibitor

Indicated for Asthma, Lung Diseases, Obstructive, Rhinitis, Urticaria

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

RECRUITING · via omalizumab · NCT05332067

ACTIVE_NOT_RECRUITING · via omalizumab · NCT02570984

UNKNOWN · via omalizumab · NCT05405478

COMPLETED · via omalizumab · NCT04037176

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. CHMP positive opinion2026-09-18

    CHMP positive opinion: Adcomfo (EMA)

    ema · regulatory · ema · via omalizumab

  2. Label change2026-08-06

    Label change: OMALIZUMAB (BLA103976)

    fda · regulatory · fda · via omalizumab

  3. Regulatory approval2024-05-16

    Approval: Omlyclo (EMA)

    ema · regulatory · ema · via omalizumab

  4. New publication2024-02-25
    Omalizumab for the Treatment of Multiple Food Allergies.

    The New England journal of medicine · 2024 · 231 citations · Europe PMC · via omalizumab

  5. Indication expanded2024-02-16

    Indication expansion: OMALIZUMAB (BLA103976)

    fda · regulatory · fda · via omalizumab

  6. Supplemental approval2023-08-17

    Supplemental approval: OMALIZUMAB (BLA103976)

    fda · regulatory · fda · via omalizumab

  7. Label change2023-03-17

    Label change: OMALIZUMAB (BLA103976)

    fda · regulatory · fda · via omalizumab

  8. New publication2022-07-30
    Omalizumab for treatment of idiopathic angioedema.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022 · 10 citations · Europe PMC · via omalizumab

  9. New publication2022-01-24
    Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.

    Allergy · 2022 · 33 citations · Europe PMC · via omalizumab

  10. Supplemental approval2021-07-22

    Supplemental approval: OMALIZUMAB (BLA103976)

    fda · regulatory · fda · via omalizumab

  11. Safety communication2014-12-11

    Drug Safety Update: Omalizumab: potential risk of arterial thrombotic events

    mhra · safety · mhra · via omalizumab

  12. New publication2011-03-01
    Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.

    The New England journal of medicine · 2011 · 651 citations · Europe PMC · via omalizumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.